Vertex Intrinsic Value Calculation – Discover if Vertex Pharmaceuticals is Worth Adding to Your Watchlist Now!
July 18, 2023
☀️Trending News
It is no secret that Vertex ($NASDAQ:VERX) Pharmaceuticals is one of the most promising and innovative biotechnology companies in the world. The company has made significant strides in recent years with products such as their cystic fibrosis treatments, helping to improve the lives of millions. With such impressive growth and accomplishments, it is understandable why investors are interested in adding Vertex Pharmaceuticals to their watchlist. When considering whether or not Vertex Pharmaceuticals is worth adding to your watchlist, it is important to evaluate a variety of factors.
The company has also recently been involved in a number of acquisitions and partnerships, which could signals continued growth. Their impressive financial performance, history of success, and commitment to innovation make them a worthwhile investment opportunity. For investors looking to benefit from the biotechnology industry, Vertex Pharmaceuticals is an excellent option to consider adding to their portfolios.
Price History
Monday was a good day for Vertex Pharmaceuticals, as the company’s stock opened at $18.9 and closed at $19.7, representing a 4.8% increase from its previous closing price of 18.8. This positive performance has caused some investors to consider adding VERTEX to their watchlists. Investors should carefully consider the company’s current performance and future outlook before making any decisions. Analyzing the company’s financial metrics, such as revenue growth, earnings per share (EPS), and debt-to-equity ratio can provide insight into whether or not the stock is a good potential investment.
Additionally, keeping up with industry news and trends can help investors gain insight into the potential future performance of Vertex Pharmaceuticals. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Vertex. More…
| Total Revenues | Net Income | Net Margin |
| 509.39 | -30.1 | -5.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Vertex. More…
| Operations | Investing | Financing |
| 81.01 | -85.35 | -24.22 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Vertex. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 725.52 | 502.04 | 1.48 |
Key Ratios Snapshot
Some of the financial key ratios for Vertex are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.9% | – | -3.4% |
| FCF Margin | ROE | ROA |
| 1.4% | -4.8% | -1.5% |
Analysis – Vertex Intrinsic Value Calculation
GoodWhale has performed an analysis of VERTEX’s fundamentals and our proprietary Valuation Line has determined that the fair value of VERTEX shares is around $22.2. Currently, VERTEX stock is traded at $19.7, which represents a fair price that is undervalued by 11.1%. This offers a great opportunity for investors to buy VERTEX shares. More…
Peers
The company was founded in 1978 and is headquartered in Berwyn, Pennsylvania. Vertex Inc has several competitors, including KLDiscovery Inc, TKC Corp, and Business-intelligence of Oriental Nations Corp Ltd.
– KLDiscovery Inc ($OTCPK:KLDI)
KLDiscovery Inc is a global provider of electronic discovery, data recovery, and litigation support services. The company has a market cap of 106.98M as of 2022 and a Return on Equity of -7.61%. KLDiscovery Inc provides services to law firms, corporations, and government agencies worldwide. The company offers a full range of services, from data collection and processing to document review and trial preparation.
– TKC Corp ($TSE:9746)
TKC Corp is a publicly traded company with a market cap of 199.69B as of 2022. The company has a Return on Equity of 9.32%. TKC Corp is a diversified conglomerate with businesses in a variety of industries including construction, real estate, hospitality, and health care. The company has a strong presence in the United States, Asia, and Europe.
– Business-intelligence of Oriental Nations Corp Ltd ($SZSE:300166)
Oriental Nations Corp Ltd is a 9.89B market cap company with a ROE of 1.79%. The company is involved in the business of intelligence and information technology.
Summary
Vertex Pharmaceuticals is a biotechnology company that specializes in cures for rare diseases. Recent data indicates that institutional investors are buying the stock, suggesting that they see potential for strong capital appreciation in the future. The company’s drug pipeline has seen positive progress and they have recently announced that their cancer therapy candidate achieved positive results in clinical trials. With the company’s progress in research and development and the increasing institutional interest, Vertex Pharmaceuticals is an attractive investment option for those looking to diversify their portfolios.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
